Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C4XD α4β7 integrin inhibitor
- Development stage
- Preclinical
- Lead developer
- C4X Discovery Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
C4XD α4β7 integrin inhibitor is an oral small molecule antagonist of the α4β7 integrin, currently under development by C4X Discovery for the treatment of inflammatory bowel disease (IBD). The drug is designed to block the interaction between α4β7 integrin on leukocytes and MAdCAM-1 on the gut endothelium, thereby preventing the trafficking of pro-inflammatory cells into the gastrointestinal tract and reducing local inflammation. Positioned as a potential best-in-class oral therapy, it supports once-daily dosing and aims to offer a more convenient alternative to existing injectable biologics. The program is currently in the IND-enabling phase, with the company utilizing a genetic biomarker to identify patients most likely to respond to the treatment.
- Other names
- α4β7 integrin inhibitor (C4X Discovery)
02
Targets
α4β7 (Integrin alpha-4 beta-7 heterodimer)
Beyond the preview
Go deeper on C4XD α4β7 integrin inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C4XD α4β7 integrin inhibitor.